Metabolic Syndrome / Obesity
DC 7903Medical Rationale
Bipolar disorder promotes metabolic syndrome through both intrinsic pathophysiology and iatrogenic medication effects. The illness itself produces HPA axis dysregulation with cortisol elevations that drive central adiposity, insulin resistance, and dyslipidemia. During depressive episodes, decreased physical activity and increased caloric intake compound metabolic risk. Critically, the medications most effective for bipolar disorder — lithium, valproate, olanzapine, quetiapine — carry substantial metabolic burden: atypical antipsychotics block hypothalamic histamine H1 and serotonin 5-HT2C receptors, increasing appetite and causing rapid weight gain of 5-15 kg within the first year. Olanzapine and clozapine additionally impair pancreatic beta-cell insulin secretion, producing treatment-emergent diabetes in 10-15% of patients.
Key Studies
McIntyre RS et al. (2010) Ann Clin Psychiatry (metabolic syndrome in bipolar disorder — prevalence and pathophysiology); Correll CU et al. (2015) World Psychiatry (metabolic effects of antipsychotics — systematic review and meta-analysis).
Filing Tips
Document metabolic syndrome criteria: waist circumference, fasting glucose, triglycerides, HDL cholesterol, and blood pressure. Pharmacy records showing bipolar medications with known metabolic side effects. Endocrinology or psychiatry nexus letter addressing both intrinsic disease mechanisms and medication-induced metabolic changes. Consider weight gain and metabolic syndrome as secondary to both the bipolar disorder itself and its required treatment. VA does not rate obesity alone, but the associated conditions (diabetes under 7913, hypertension under 7101) are separately ratable.